Dr. Jessica Allegretti discusses the recent abrupt ending of the CP101 clinical program and why options are important for patients with #Cdiff: https://t.co/zohpEkdELL pic.twitter.com/LHqctmfbA4— HCPLive (@MDMagazine) February 8, 2023
Difficile Infections (Clostridium Difficile Associated Disease) Market is expected to be worth US$ 1
The worldwide Difficile Infections (Clostridium Difficile Associated Disease) Market is predicted to reach a valuation of US$ 809 Million in 2023, with a CAGR of 6% predicted from 2023 to 2033.Clostridium difficile infection (CDI) is a disease caused by toxic compounds produced by the spore-formi...
CEO Spotlight: Acurx Pharmaceuticals CEO Confident His Phase 2b Ibezapolstat Drug Candidate Can Earn Front-Line Designation to Treat C. difficile
Acurx Pharmaceuticals CEO David Luci tells Soulstring Media Group why he thinks his company and lead drug candidate, Ibezapolstat, can be a front-line treatment against C. difficile New York, New York--(Newsfile Corp. - February 7, 2023) - Soulstring Media Group, Llc., a market research, aggregator, and digital media production and management company specializing in creating and syndicating content from publicly traded and private companies, announced today that it had published an in-depth inte
Clostridium Difficile Infection Treatment Market Next Big Thing | Merck, Baxter International, Sanofi
The new report by Stratagem Market Insights titled Global Clostridium Difficile Infection Treatment Market Outlook Report 2022 2030 gives an in depth analysis of the global Clostridium Difficile Infection Treatment market assessing the market based on its segments like Type ...
Looking Beyond C difficile: The Potential of the Gut Microbiome
Dr. Elizabeth Garner speculates the FDA approval of RBX2660 for recurrent C difficile infection will pave the way for more restorative microbiome therapies.
Cb mig q fod h rwczov l3d3dy5jb250 y wdpb25sa x zl lm nvb s92a wv3 l3 nlci0x m dktc2lnbmlma w nhbn rse s1pb x byb3 zl zc1xd w fsa xr5 lw9m l wxp zm ut zm9y lx jl y3 vycm vud c1jb g9zd h jp z glva w rlcy1ka w zma w npb g utc gf0a w vud hpsaqa
.@VedantaBio is developing oral drugs that are designed to deliver defined bacterial consortia to treat diseases linked to the #microbiome including #CDiff & #IBD. A Phase 3 trial of Vedanta’s VE303 for the treatment of #rCdiff is planned to begin in 2023. https://t.co/Xyew5il3Ba— MTIG (@MTIG_News) January 31, 2023
Happy to share our work in @JAMANetworkOpen In our study patients treated with SER-109 (an oral microbiome therapeutic) had significantly greater improvements in disease-specific HRQOL scores compared with patients treated with placebo through 8 wks #cdiff https://t.co/zL1iUg3LBz pic.twitter.com/77wCrrTIlv— Abhishek Deshpande (@abhishek_dp) January 30, 2023
Clostridium Difficile Infections Market Drugs are expected to get launched during the study period 2019-2032 | Major Companies- Merck, Optimer Pharmaceuticals (Acquired by Cubist Pharmaceuticals, Inc.), and others.
Design of 8-mer Peptides that Block Clostridioides difficile Toxin A in Intestinal Cells - PubMed
Infections by Clostridioides difficile , a bacterium that targets the large intestine (colon), impact a significant number of people worldwide. Bacterial colonization is mediated by two exotoxins: toxins A and B. Short peptides that can inhibit the biocatalytic activity of these toxins repres …
ADS024, a Bacillus velezensis strain, protects human colonic epithelial cells against C. difficile toxin-mediated apoptosis - PubMed
Clostridioides difficile infection (CDI) causes intestinal injury. Toxin A and toxin B cause intestinal injury by inducing colonic epithelial cell apoptosis. ADS024 is a Bacillus velezensis strain in development as a single-strain live biotherapeutic product (SS-LBP) to prevent the rec …
Gut Punch: Finch’s Flagging Microbiome Program Folds, Leading to 95% Staff Cut - MedCity News
Clinical trial setbacks and financial challenges have led Finch Therapeutics to stop a Phase 3 study for its lead microbiome program, a potential treatment for recurrent C. diff infection. As Finch seeks buyers for its remaining assets, the biotech is laying off most of its staff in a corporate restructuring.
The gut microbiome plays a critical but poorly understood role in how drugs work or don't work in the body. It also presents therapeutic possibilities unto itself.
Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets | MarketScreener
SOMERVILLE, Mass., Jan. 24, 2023 -- Finch Therapeutics Group, Inc. today announced its decision to discontinue the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection and focus on... | January 24, 2023
.@ServatusLtd's drug development platforms contain engineered proteins for the treatment of autoimmune diseases and live biotherapeutics (LBPs) for the treatment of inflammatory conditions and bacterial infections including #IBD, #CDiff and H. pylori. https://t.co/eUgiukdHkL— MTIG (@MTIG_News) January 23, 2023
Antibacterial Activity of Crocus sativus L. Petals Extracts against Foodborne Pathogenic and Spoilage Microorganisms, with a Special Focus on Clostridia - PubMed
In recent years, there has been a growing interest in the use of novel antimicrobial agents able to inhibit or kill food-borne bacteria or to interrupt the onset of food spoilage. Crocus sativus L. petals, typically considered as waste obtained from saffron spice production, could be a source …
Immuron Receives European Patent on Drug Composition to Treat Clostridioides difficile Associated Disease | MarketScreener
MELBOURNE, Australia, Jan. 17, 2023 -- Immuron Limited , an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic... | January 17, 2023
Discovery of potential phytochemicals as inhibitors of TcdB, a major virulence factors of Clostridioides difficile - PubMed
Clostridioides difficile is a gram-positive bacterium which is associated with different gastrointestinal related infections, and the numbers of cases related to it are continuously increasing in the past few years. Owing to high prevalence and development of resistance towards available anti …
Effect of polysaccharide derived from dehulled adlay on regulating gut microbiota and inhibiting Clostridioides difficile in an in vitro colonic fermentation model - PubMed
Human body can digest only a few sugars with a low degree of polymerization. The rest of the carbohydrates become food for gastrointestinal symbiotic bacteria, affecting gut microbiota composition and human health. Adlay is a medicinal and food homologous crop. The study aims to determine whether de …
Research seeking to outsmart C. diff achieves sustained 50% decrease in infections across eight hospitals
According to recent research conducted at several member hospitals that are part of Trinity Health and published in Infection Control and Hospital Epidemiology, optimized environmental cleaning is the key to effectively reducing C. diff transmission inside hospitals.
Nature Reviews Gastroenterology & Hepatology - The gut microbiome field is shifting from association to modulation. Microbiota-based treatments come in many shapes and sizes, ranging from...
Systematic Design of Adenosine Analogs as Inhibitors of a Clostridioides difficile-Specific DNA Adenine Methyltransferase Required for Normal Sporulation and Persistence
Antivirulence agents targeting endospore-transmitted Clostridioides difficile infections are urgently needed. C. difficile-specific DNA adenine methyltransferase (CamA) is required for efficient sporulation and affects persistence in the colon. The active site of CamA is conserved and …
